Polynovo (ASX:PNV) share price rises after "positive" FY22 quarterly update

Polynovo shares are rising after the company's FY22 first quarter update.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Polynovo Ltd (ASX: PNV) share price went up around 0.5% after the company delivered its quarterly update for the first quarter of FY22.

For readers that don't know what Polynovo does, it's a business that develops medical devices that use the patented bioabsorbable polymer technology called Novosorb.

Novosorb is a group of medical grade polymers that can be 'expressed' in a variety of physical formats. Novosorb polymers have advantageous properties such as biocompatibility and design flexibility. These devices help tissue repair, before they biodegrade.

It has expanded its manufacturing facility and headquarters in Melbourne, as it prepares for growth.

Polynovo FY22 first quarter update

Geographically, the company has seen different levels of performance in different markets.

Europe

Polynovo said that in the EU, face to face meetings are back, conferences are being attended and hospital access has returned to near normal levels.

Management are expecting to sign additional distributors in the second quarter, including in Cyprus and the Czech Republic. Other jurisdictions, such as France and Portugal, are in negotiation. The EU has performed "well" with growth of 204% compared to the first quarter of FY21.

A new third party logistics distribution centre in Belgium is operational and filling sales orders with deliveries to Germany, Finland and an order from Italy being filled this week.

The company said that all indications are that orders will commence soon to other distributors in Poland, Turkey and Greece.

A relaxation of COVID-19 restrictions in UK and Irish hospitals has been a "positive" for the business. It has also been buoyed by some clinical trials. FY22 first quarter sales were up 327% on the same quarter last year.

US

Management called the trading in the US "patchy". Polynovo said it has had limited access to American hospitals and surgeons. Despite that, it achieved a record number of new accounts opened in the first quarter, with total accounts in the US up 65% on the first quarter of FY21. Its enlarged sales team is making progress into new territories.

July and August sales were up 56% year on year, whilst September sales were mixed. This resulted in the first quarter sales being up 21%.

Australia and New Zealand

Polynovo said that its local sales were impacted by the long lockdowns in New South Wales and Victoria. It's expecting sales to improve as COVID-19 restrictions ease in the second quarter of FY22.

Leadership commentary

New accounts in its direct markets (excluding distributor markets) in the first quarter of FY22 were 56% higher than the FY21 first quarter.

The managing director of Polynovo, Paul Brennan said:

A strong start to the first quarter of FY22 follows the strong fourth quarter finish in FY21 despite continuing COVID restriction in the southern states of the US. Our teams are expanding and signing new accounts and as patient access improves, we expect this will translate into strong sales.

Polynovo share price snapshot

Over the past year, the Polynovo share price has actually fallen by 23%. However, in the last five years it has risen 467%.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »